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Background: The Universal HIV Test and Treat (UTT) strategy represents a challenge for science, but is also a challenge
for individuals and societies. Are repeated offers of provider-initiated HIV testing and immediate antiretroviral therapy
(ART) socially-acceptable and can these become normalized over time? Can UTT be implemented without
potentially adding to individual and community stigma, or threatening individual rights? What are the social, cultural
and economic implications of UTT for households and communities? And can UTT be implemented within capacity
constraints and other threats to the overall provision of HIV services? The answers to these research questions will be
critical for routine implementation of UTT strategies.
Methods/design: A social science research programme is nested within the ANRS 12249 Treatment-as-Prevention
(TasP) cluster-randomised trial in rural South Africa. The programme aims to inform understanding of the (i) social,
economic and environmental factors affecting uptake of services at each step of the continuum of HIV prevention,
treatment and care and (ii) the causal impacts of the TasP intervention package on social and economic factors at the
individual, household, community and health system level. We describe a multidisciplinary, multi-level, mixed-method
research protocol that includes individual, household, community and clinic surveys, and combines quantitative and
qualitative methods.
Discussion: The UTT strategy is changing the overall approach to HIV prevention, treatment and care, and substantial
social consequences may be anticipated, such as changes in social representations of HIV transmission, prevention, HIV
testing and ART use, as well as changes in individual perceptions and behaviours in terms of uptake and frequency of
HIV testing and ART initiation at high CD4. Triangulation of social science studies within the ANRS 12249 TasP trial will
provide comprehensive insights into the acceptability and feasibility of the TasP intervention package at individual,
community, patient and health system level, to complement the trial’s clinical and epidemiological outcomes. It will
also increase understanding of the causal impacts of UTT on social and economic outcomes, which will be critical for
the long-term sustainability and routine UTT implementation.
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Four large-scale cluster randomized trials are ongoing in
Eastern and Southern Africa to measure the efficacy of a
Universal Test and Treat (UTT) approach in ‘real life’ [1]:
ANRS 12249 TasP (Treatment–as-Prevention) in South
Africa [2,3]; HPTN 071 PopART in South Africa and
Zambia [4,5]; SEARCH in Kenya and Uganda [6] and the
Botswana Combination Prevention project [7]. All four
trials rely on some form of longitudinal population-
based HIV surveillance approach to evaluate changes in
HIV prevalence and, most importantly, in HIV inci-
dence over time.
Following Granich and colleagues’ model published in
the Lancet in 2009 [8], UTT interventions are built
around two main components:
1. HIV counselling and testing of all, or nearly all,
members of a defined population in a geographical
area to identify those already infected with HIV or
diagnosed but not yet linked to care, and thereafter
regular and repeat HIV testing of those who test
HIV-negative to identify new positives as early as
possible after seroconversion;
2. initiation of life-long antiretroviral treatment (ART)
as soon as possible after HIV diagnosis, regardless of
CD4 count, while supporting other preventive be-
haviours (e.g. consistent condom-use with all part-
ners) to further enhance the expected benefits of
immediate ART.
Reports modelling the effects of UTT [9,10] suggest
that the significant prevention benefits (i.e. statistically
significant reductions in HIV incidence) necessary to
warrant taking UTT interventions to scale are obtained
only when very high levels of uptake of the two key
components of the UTT strategy are achieved and sus-
tained – as high as 90% of HIV-negative people tested
for HIV every year and 90% of HIV-infected people
starting ART [8]. Yet data published so far, highlight the
challenge of reaching such high uptake rates of HIV test-
ing and HIV care, even before considering a UTT strategy
itself. A recent meta-analysis of home-based voluntary
HIV testing in sub-Saharan Africa showed that the pro-
portion of people who accept home-based HIV testing
ranged from 58.1% to 99.8% overall (pooled percentage
83.3%), and from 58.1 to 91.8% in South Africa specifically
[11]. This review did not present data on repeat HIV test-
ing, however the few available reports on uptake of con-
secutive HIV testing campaigns show a 75-80% uptake of
a second test among those tested the first time [12,13]. In
terms of linkage to care and ART initiation, a recent
meta-analysis of sub-Saharan African data published be-
tween 2001 and 2012, showed that, for 100 patients with a
positive HIV test, 72 had a CD4 count performed, 40 wereeligible for ART and only 25 started [14]. The 2013 World
Health Organisation (WHO) guidelines on ART eligibility
recommend initiation of ART at a CD4 count threshold of
500 cells/mm3 [15], but these new recommendations are
not yet implemented by most African countries [16]. Thus
there is little, if any, data on the acceptability and uptake
of early or immediate ART (i.e. CD4 > 350 cells/mm3). In
this context, and with UTT not being a single intervention
of HIV testing or initiation of ART, but rather a complex
combination, considerable barriers to the implementation
and uptake throughout the UTT cascade can be antici-
pated [17,18].
As much as UTT represents a challenge for scientists,
public health authorities and health care providers, it is
also likely to be a challenge for individuals and societies.
There is limited research addressing how communities
respond to participating in a research programme that
involves substantial normative social change in commu-
nity cultures and perceptions. South Africans have been
exposed to rapidly changing discourses from public au-
thorities with regard to the cause of HIV/AIDS, the ways
to prevent HIV infection and to care for people with
HIV. UTT as a new approach to deal with the epidemic
in the community might raise distrust from the commu-
nity or, conversely, strong support. Preliminary qualita-
tive enquiry [19,20] and discussion with community
leaders and key informants in South Africa suggest that
the UTT approach is welcome, but what the individual
and community response to the interventions will be is
largely unknown.
We constructed a multi-disciplinary research programme
implemented as part of the ANRS 12249 Treatment-as-
Prevention (TasP) trial in South Africa. In this paper, we
first briefly present the overall trial design. We then out-
line the research questions and objectives that each com-
ponent of our multi-disciplinary research programme
aims to address. We describe in detail the research
methods and specific data collection tools being imple-
mented. Finally we discuss some of the emerging issues
raised by UTT strategies that are unlikely to be answered
in the short-term by any of the ongoing trials.
Methods/design
The ANRS 12249 TasP trial
The protocol of the TasP trial, registered on clinical-
trials.gov (NCT01509508), has been described elsewhere
[2]. In summary, the main hypothesis of the TasP trial is
that HIV testing of all adult members of a community,
followed by immediate ART initiation of all, or nearly
all, HIV-infected participants regardless of immuno-
logical or clinical staging, will prevent onward transmis-
sion and reduce HIV incidence in this population. The
TasP trial is a cluster-randomised trial implemented in
the Hlabisa sub-district, in rural northern KwaZulu-
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000 Zulu-speaking inhabitants. The HIV prevalence in
the sub-district is one of the highest in the world, with
around 29% of adults infected with HIV [21].
The UTT strategy being tested in the cluster-randomised
TasP trial has two main components (the trial intervention
package): universal and repeat home-based HIV testing of
all resident adults and immediate ART initiation. In
both trial arms, rounds of home-based HIV testing are
repeated every six months. All trial participants identi-
fied as HIV-infected are referred to a local TasP trial
clinic situated in the trial cluster in which they live. In
the control clusters, HIV infected adults are offered
ART according to current South African guidelines (i.e.
at less than 350 CD4 cells/mm3 or WHO stage 3 or 4
or pregnancy). In the intervention clusters, all HIV in-
fected adults seen in TasP trial clinics are offered the
opportunity to begin ART immediately regardless of
CD4 count or clinical staging.
Implementation of the trial followed a two-phased ap-
proach. The first phase started with four clusters in
March 2012, six additional clusters started in January
2013, with the first round completed in all 10 clusters in
March 2014 [22]. In phase 2, started in June 2014, the
trial continues for two further years (4 rounds) in the 10
clusters from the first phase and extended to 12 new
clusters. In total, the trial is implemented in 22 (2 × 11)
clusters, expected to contribute 58 cluster-years of
follow-up with an average cluster size of 1,000 residents
16 years or older, of whom an estimated 200 are living
with HIV.
Research questions addressing social issues within the
TasP trial
Implementation of the trial intervention package in the
Hlabisa sub-district will modify the HIV prevention and
care landscape, with a likely increased number of people
aware of their HIV status and with more HIV-infected
people having the opportunity to initiate ART immedi-
ately after HIV diagnosis.
The social science research programme embedded in the
ANRS 12249 TasP trial aims to comprehensively inform
understanding of the (i) social, economic and environmen-
tal factors associated with uptake of each component of
the trial intervention package (the HIV treatment and care
“cascade” [23]); (ii) overall journey of trial participants
through the continuum of HIV prevention and care; and
(iii) social and economic impact of the trial intervention
package at individual, household, community, population
and health system level. These dimensions are intrinsically
linked together, for example, changes in social norms are
likely to have an impact on HIV testing uptake and linkage
to care, and at the same time, may change as HIV testing
and care practices evolve [24].Table 1 summarizes the research questions addressed
by the social research programme, grouped according to
the following main topic areas: community perceptions
and experiences, HIV testing, linkage to HIV care, HIV
care and treatment, sexual behaviours and HIV risk and
prevention practices, and economic impacts and eco-
nomic value.
Community perceptions and experiences
Implementation of immediate ART with the aim of bring-
ing about community prevention benefits is a new con-
cept, different from ART initiation for the sole individual
clinical benefit. Treatment-as-prevention or “treatment is
prevention” may change the social representations of
ART, HIV transmission risk and HIV infection itself and
in turn, could lead to change in HIV sexual risk and HIV
prevention practice. Such a large-scale and intensive inter-
vention has the potential to increase stigma and
marginalization of HIV-infected people, or may, on the
other hand, contribute to normalization of HIV and
greater acceptability of people living with HIV, with in-
creased social support. Could universal HIV testing in the
trial community induce a form of “required” HIV status
disclosure to partners, family and other community mem-
bers? For those who do not want to disclose their HIV sta-
tus, how feasible will it be to keep this knowledge
confidential in a context where everyone or almost every-
one will have been tested? Depending on these effects, re-
peat HIV testing uptake, as well as linkage to care and
treatment, acceptability for people diagnosed HIV positive
during home-based testing may differ. It is crucial to
understand community perceptions of UTT and identify
social norms that may change and affect the acceptability
of the trial intervention package [25].
HIV testing
A UTT strategy by its nature raises questions about per-
ceptions and practices of HIV testing in the study popu-
lation. Home-based HIV testing has been shown to be
an acceptable intervention in KwaZulu-Natal [26] but
acceptability and feasibility of providing repeated home-
based testing, as frequently as twice a year, has not been
assessed. How effective is home-based HIV testing
programme in reaching the entire resident population of a
community? Does the acceptability of home-based HIV
testing differ according to previous exposure to/experi-
ence of HIV (testing or care), personally, within the family
or within the immediate surroundings? Does home-based
HIV testing complement or supplement the current HIV
testing provision in the trial area? Who systematically re-
fuses home-based HIV testing? Do repeated campaigns of
home-based HIV testing allow for the early identification
of individuals recently infected by HIV? Finally, what im-
pact, if any, will the rounds of repeat testing and the
Table 1 Summary of research questions addressed within the ANRS 12249 TasP trial social research programme and triangulation of associated surveys and
sub-studies
Key research areas Research questions Home-based
survey
Clinic-based
survey
Community
qualitative
study
Costs assessment
and time-motion
survey
Health care
professionals
survey
Community perceptions
and experiences
What are the community perceptions and experiences of the trial
intervention package?
X
How does the trial intervention package of HIV testing and care fit
with community’s experience of Department of Health service provision?
X
Can communities be successfully engaged in the trial intervention
package, i.e. does community stigma towards PLWHIV decrease
and social support improve over the duration of the trial?
X X X
HIV testing What are the individuals and community attitudes to and perceptions
of HIV testing and repeat HIV testing, and do these change over
the duration of the trial?
X X
What are the social, economic and environmental barriers to initial
and repeat home-based HIV testing, and do these change over
duration of the trial?
X X
What is the impact of repeat HIV testing on disclosure and
conjugal relationships and do these change over the duration of
the trial?
Linkage to HIV care What are the social, economic and environmental barriers to entry
into care and do these change over duration of the trial?
X X X
How acceptable to individuals and the community is the trial model
of HIV care?
X X
HIV care and treatment What are community and individual expectations, perceptions and
knowledge of immediate ART over time?
X X X
What are the social, economic and environmental barriers to
immediate ART and do these change over the duration of the trial?
X X
What is the impact of immediate ART on adherence and retention
in care and how does it changes over time?
X X
What are the causal impacts of immediate ART for quality of life
and patient satisfaction?
X
What are the psycho-social impacts (disclosure status, union-break
up, social support, perceived stigma, depression, gender-based
violence) of immediate ART?
X X
What are community and individual expectations, perceptions and
knowledge of immediate ART and do these change over time?
X X X
Sexual behaviours
and HIV risk/prevention
practices
What are the most common HIV sexual risk behaviours and practices
(e.g. multiple concurrent partners)?
X X
What are the main prevention strategies (change in sexual practices,
condom use, male circumcision) and do these changes over the
duration of the trial?
X X
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Table 1 Summary of research questions addressed within the ANRS 12249 TasP trial social research programme and triangulation of associated surveys and
sub-studies (Continued)
Key research areas Research questions Home-based
survey
Clinic-based
survey
Community
qualitative
study
Costs assessment
and time-motion
survey
Health care
professionals
survey
What are the effects of immediate ART on sexual behaviours and HIV
prevention practices?
X X
Economic impacts
and economic value
What is the causal impact of the trial intervention package on employment,
household welfare and private health care spending?
X X
How does the trial intervention affect quality of care and health systems
outcomes, such as impacts on health care professionals (training, working
conditions, practices, perceptions) and health care capacity?
X
What are the cost and the cost-effectiveness of the trial intervention package
(home-based testing, immediate ART) in this rural South African context? What
is the full social net value of the trial intervention package?
X X X X
What is the feasibility and financial sustainability (budget impact) of the trial
intervention package (health system level) in this rural South African context?
X X X X
ART: antiretroviral therapy; DoH: department of health; PLWHIV: people living with HIV.
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couples and their personal and sexual relationships, in
particular in terms of HIV status disclosure and partner-
ship dissolution?
Linkage to HIV care
Linkage to HIV care is still a major challenge for most
ART programmes in sub-Saharan Africa [27]. But to en-
sure maximum reduction of HIV incidence, a UTT strat-
egy requires that HIV-infected individuals are linked to
care as soon as possible after seroconversion. How ef-
fective is early linkage to care in the context of repeated
rounds of home-based HIV testing and what are the so-
cial, economic and environmental barriers? How do
community members perceive TasP trial clinics dedi-
cated only to HIV-infected individuals? Does the per-
spective of immediate ART initiation following HIV
diagnosis (vs. according to current guidelines) alleviate/
reinforce the various barriers to entry in care?
HIV care and treatment
There is growing evidence that early treatment in HIV
positive individuals is associated with improved clinical
benefits compared with delayed treatment [28,29]. Be-
sides clinical benefits, immediate ART is likely to also
affect psychosocial and behavioural outcomes such as
adherence to ART, quality of life and retention in care,
but the direction and magnitude of these effects are un-
known. Will adherence be lower for people who do not
experience the need for treatment as they are still in good
health when initiating ART? Will quality of life decrease if
individuals experience side-effects or if the treatment is
not well accepted? Or will universal treatment generate a
higher acceptability of HIV infected people and increased
awareness of the benefits of treatment, including its pre-
vention benefits, thus improving adherence to treatment
and quality of life of HIV positive individuals initiating
ART immediately? It is also plausible that there is a gain
in quality of life due to UTT, at least among some pa-
tients, because they can utilize ART as soon as they want
to, rather than being told that they will have to wait until
they suffer from more advanced HIV disease.
Sexual behaviours and HIV risk/prevention practices
The nature and magnitude of the social effects of UTT
are unknown and difficult to predict, especially on sex-
ual behaviours, HIV risk and prevention practices. A key
question is whether the overall effect of immediate ART
on reducing HIV incidence at the community level is
counterbalanced by potential disinhibition effects on
sexual behaviours? Could the knowledge of the prevent-
ive effect of ART induce decreased condom use? Recent
work in the same area found no evidence of increased
sexual risk-taking at the population level following ARTavailability and even protective changes in some behav-
iours [30]. Emerging literature based on clinical trials
assessing early ART (at CD4 > 350) also suggest that
condom use is comparable among HIV-infected people
treated below and above the 350 CD4 threshold, and
rates of partnership acquisition and dissolution are also
similar [31,32]. However, such effects need to be con-
firmed when early ART is scaled up at the population
level and used for long periods of time.
Economic impacts and economic value
ART can lead to changes in employment and household
welfare [33] raising the issue of the economic impact of
the trial intervention package at household and commu-
nity levels. Will expanding access to immediate ART in-
duce extra expenses for individuals and households such
as transportation cost, food, children’s supervision, work
days lost, for example? Will immediate ART avert the
economic losses that people experience before they initi-
ate ART during comparable late disease stages [33] or
will it lead to economic productivity losses because of
ART side effects and time lost due to health care
utilization among patients who are not yet experiencing
any severe symptoms of HIV disease [34]? Or con-
versely, will it improve economic and social outcomes
because the health losses due to advanced HIV disease
are prevented rather than treated?
UTT also raises important issues about the feasibility
and financial sustainability of such a public health strategy
given existing resources. These include the cost of the trial
intervention package and its cost-effectiveness, as well as
the resource needs and budgetary impact over the long
term. Difficult working conditions, inadequate training
and lack of career development have been shown to have
an impact on human performance and may jeopardize
quality of care, as well as HIV treatment delivery [35]. To
what extent do the human resources constraints challenge
the implementation of a UTT strategy in the trial area?
Research methods
To address the many social research questions raised by
the trial intervention package implemented within the
ANRS 12249 TasP trial, we adopted a multidisciplinary,
multi-level and mixed-methods research approach. We
designed several surveys, at the community, household,
individual, and clinic level, combining quantitative and
qualitative methods (Figure 1). Survey results will be tri-
angulated so as to provide a comprehensive response to
each of the questions outlined in Table 1.
Home-based survey
The home-based survey is repeated at each round of
home-based HIV testing. It consists of a series of face-
to-face questionnaires administered by fieldworkers/HIV
Figure 1 Components of the ANRS 12249 TasP trial social research programme: surveys, populations and tools.
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household level to the head of household (the household
registration questionnaire and the household assets ques-
tionnaire) (see Table 2) and one questionnaire adminis-
tered at the individual level to each household memberTable 2 Items documented in the household questionnaires
Home-based household questionnaire
Household composition and basic socio-demographic (gender and age) cha
Changes in household composition (including in-out migrations/mortality/ne
Household assets
Food securitywho is eligible and willing to participate in the trial (see
Table 3). These household and individual data will con-
tribute to profiling the individuals and population groups
who are not reached by the trial intervention package or
who decline part or all of it.Registration visit Follow-up visits
racteristics X
wly eligible) X
X X
X X
Table 3 Items documented in the individual questionnaires (IQ)*
Phase 1 1st
contact IQ1
Phase 1 2nd
contact IQ2**
Phase 1 3rd
contact IQ3
Phase 2 IQ
Home-based individual questionnaire
Education X X X
Employment and income** X X X X
Marital status X X X X
Parenthood X X X
Attitudes and beliefs about HIV infection and treatment* X X X X
HIV testing behaviour X X X
Attitudes and beliefs about HIV testing X X X
Knowing someone with HIV infection X X X
Self-reported knowledge of HIV status X X X X
Partnerships and sexual network patterns X X X
Prevention and risk behaviours:
- Alcohol X X X X
- Condom use X X X
- Male circumcision X
Quality of life X X X
Stigma towards PLWHIV X X X
Health care use and expenditure X X
Safety and security X X
Home-based HIV testing
Dried Blood Spot X X X X
Home HIV counselling and rapid testing X X X X
*The individual questionnaire is administered at each home-based testing rounds, i.e. theoretically every six months. Phase 1 took place between March 2012 and
May 2014. Phase 2 started in June 2014.
**Questions in IQ1/IQ3 and IQ2 are slightly different. All of them are incorporated in the phase 2 IQ. The IQ2 module is a shorter version of the IQ1/IQ3 module.
PLWHIV: people living with HIV.
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is comprised of items that have been used in previous
Africa Centre research studies, particularly work con-
ducted in the Africa Centre Demographic Surveillance
Area (e.g. socio-demographics [36], sexual behaviour
and sexual relationship [30], health care expenditure
[37], acceptance of HIV counselling and testing and/or
Dried Blood Spot [36]). In addition, to assess quality of
life, we use the EQ-5D scale [38], a short five-item ques-
tionnaire validated in the isiZulu language by the Euro-
Qol group [39].Clinic-based survey
The clinical follow-up of patients enrolled in TasP trial
clinics has been described in detail elsewhere [2]. We
describe here the clinic-based survey implemented in
each of the TasP trial clinics. All HIV-positive adults
who choose to be followed in these TasP trial clinics
are eligible to participate in the survey, regardless of
their eligibility for ART. Trial participants who chooseto remain in care in the Department of Health (DoH)
clinics are not included in this survey for practical
reasons.
The clinic-based survey is composed of several ques-
tionnaires, some administered by the TasP trial clinic’s
ART counsellor and others by an independent inter-
viewer. During the first clinic registration visit, the ART
counsellor administers a baseline questionnaire, de-
signed as an additional module to the baseline informa-
tion collected by the Department of Health (DoH case
report form). HIV-infected patients are then invited to
participate in six-monthly follow-up questionnaires, ad-
ministered by an independent interviewer, in order to
limit social desirability bias; the ART counsellor also ad-
ministers a short questionnaire for a small number of
non-sensitive questions such as economic situation (see
Table 4).
A large part of the clinic-based questionnaires is com-
prised of items used elsewhere in this trial (e.g. sexual
behaviour and sexual relationship or health care expend-
iture questions included in the individual home-based
Table 4 Items documented in the clinic-based questionnaires
Topic M0 M6 M12 M18 M24 M30 M36 M42 M48
ART perception C
ART knowledge I I I I I I I I
Self-reported adherence*, I I I I I I I I
Disclosure and couple union C I I I I I I I I
Sexual behaviour I I I I I I I I
Gender attitudes and violence I I I I I I I I
Social and community support C I I I I I I I I
Alcohol consumption C C C C C C C C C
Depression and anxiety C I I I I I I I I
Stigma and discrimination I I I I I I I I
HIV Quality of life I I I I I I I I
Economic situation: income, consumption and wealth C C C C C C C C C
Health expenditure C I I I I I I I I
Time and costs associated with the clinic visit C C C C C C C C C
Satisfaction with care I I I I I I I I
C: ART counsellor-administered questionnaire; I: interviewer-administered questionnaire; *for participants on ART only.
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research studies (e.g. satisfaction with care [40] or social
support [41,42].
Internationally recognized tools and validated meas-
urement scales are used to assess violence, adherence,
depression, stigma, and quality of life.
– Violence and gender attitudes are documented using
an extract of the WHO Multi-country Study on
Women’s Health and Domestic Violence against
Women [43].
– In addition to the assessment of adherence during
the clinic-follow-up based on visual analogue scale,
pill identification test and pill count [44], we assess
self-reported adherence using a scale, validated in
another African country context, designed to limit
both recall and social desirability bias [45-48]. This
tool includes several questions related to dose taking
during the previous four days and adherence to the
dosing time schedule during the previous four
weeks. Adherence scores, which are computed using
a validated algorithm allow classification of patients
into highly adherent, moderately adherent and
poorly adherent which has been shown to be
significantly associated with viral load [46]. Another
item focusing recording occurrence of treatment
interruptions lasting more than two consecutive
days during the previous four weeks, is also included
as it has that has already been tested in another
context African context [48] and has been found to
be a predictor of resistance development in
sub-Saharan setting [49].– Stigma perceived in people living with HIV
(PLWHIV) and experience of discrimination is
assessed using the HIV/AIDS stigma instrument for
PLWHIV (HASI-P) [50]. This scale has been
developed to measure perceived stigma among
PLWHIV in Southern African countries and its
psychometric properties have been validated in
different languages including isiZulu [50].
– Depression and anxiety are measured in the baseline
questionnaire using the shortened version of the
Patient Health Questionnaire, the PHQ-4 [51,52] and
then in the follow-up questionnaires using the PHQ-
9 [53,54]. A meta-analysis showed that PHQ-9 is ac-
ceptable in a wide range of settings, countries and
populations [55] and both versions of the scale
(PHQ-9 and PHQ-4) have been used in isiZulu in
ongoing research by the Africa Centre.
– Quality of life is assessed using a scale specifically
built for HIV infection - the “Patient Reported Out-
comes Quality Of Life, specific to HIV” (PROQOL-
HIV). The PROQOL-HIV instrument comprises 43
items distributed throughout a comprehensive set of
nine dimensions related to the quality of life of
PLWHIV: general health, physical health and symp-
toms, treatment impact, health concerns, intimate
relationship, emotional distress, body change, stigma
and social relationships. Its psychometric properties
have been evaluated and validated in different con-
texts (Australia, Brazil, Cambodia, China, France,
Senegal, Thailand, USA) including sub-Saharan
Africa and the instrument has been shown to be
sensitive to differences in culture and gender [56].
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The community qualitative study, implemented during
the first phase of the trial in the four initial clusters, em-
ploys a combination of repeat one-on-one semi-structured
interviews and repeat focus group discussions using com-
plementary participatory methods (see Table 5).
Semi-structured interviews A selected number of HIV
positive and HIV negative participants (n = 20), compris-
ing randomly mixed and purposefully selected groups of
young and old, male and female participants are
approached to participate in the semi-structured inter-
view study. The HIV status of participants recruited
from homes (n = 15) is unknown to the facilitator, unless
disclosed by the participant during the interview, while
individuals recruited from TasP trial clinics (n = 5) are
known to be HIV infected. All participants are invited to
participate in in-depth semi-structured interviews lasting
60–90 minutes. From this initial group of twenty (n =
20), ten (10) are invited to repeat the interview two more
times, over 18 months. Each of the interviews has a spe-
cific purpose (see Table 5).
Repeat focus group discussions Repeated focus group
discussions with different community groups capture the
overall impact of the UTT intervention across different
sectors of the community. The focus group membership
is purposively sampled by the facilitator and the Africa
Centre Community Engagement officer. The members
of each focus group also serve as key informants and ex-
pert advisors to help the trial team ensure that commu-
nity entry, awareness and education plans are fully
developed for the second phase of the trial. The four
groups are comprised of: (i) mixed gender older (35 years
and above); (ii) traditional healers (mixed age and gen-
der); (iii) mixed gender youth (16–34 years old); (iv)Table 5 Description of areas and issues coveed in repeat in-d
discussions
Meeting 1 Meeting 2
In-depth
interviews
n = 20 n = 10
Topic Access to health care in the
community & knowledge
of HIV status
Stigma induced by
attending TasP trial clin
Approach used Personal experiences
and representations
Personal experiences
and representations
Focus group
discussions
n = 4 n = 4
Topic Health care services in
the community
Community and individ
experiences and percep
of UTT
Approach used Individual and group
narratives
Individual and group
narratives
ART: antiretroviral treatment; TasP: treatment-as-prevention; UTT: universal test andmixed age and gender (16 years old and above). Each
group meets on four separate occasions (see Table 5)
with the same facilitator for a maximum of 2 hours, with
specific thematic issues for each session. All sessions are
audio recorded with participants’ written informed
consent.
The last meeting includes a community walk which in-
volves walking with community members through the
community, observing, asking questions, and listening to
things and places that are significant to community
members in relation to HIV testing and treatment. In
addition to the community walk, each participant is
given a camera and asked to take five or more photos of
things that they believe pose challenges for HIV testing
and immediate ART initiation [57]. In the focus group
discussion, each participant is given a chance to discuss
the photos that best represent the barriers and facilita-
tors of HIV testing and immediate ART initiation.
Costs assessment and time-motion survey
The cost of the intervention corresponds to the monetary
value of resources used in producing the intervention. It is
assessed by quantifying the different types of resources
used for the implementation of the two main components
of the intervention, by identifying their unit costs and fi-
nally by multiplying the quantities of each resource by its
unit costs. Resources used for the implementation of the
trial intervention package are obtained from the trial ac-
counting/finance team and from activity reports for the
home-based HIV testing component and from standard-
ized clinical record forms (CRF) for the HIV care and
treatment component. Unit costs are obtained mainly
from the trial accounts team for both components and
completed by additional external sources for care and
treatment subsidised in the trial (like ART) or provided by
DoH clinics (like hospitalization).epth semi-structured interviews and focus group
Meeting 3 Meeting 4
n = 10
ics
Social support and disclosure
Understanding of benefits of UTT
Personal experiences and
representations
n = 4 n = 4
ual
tions
Local cultures that facilitate and
support regular and repeat testing
and HIV status disclosure
Facilitators and barriers
to HIV testing and ART
uptake
Individual and group narratives Community walk
treat.
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sources used for the intervention production from those
specifically consumed by research activities, which
should be excluded from the cost calculation. The time-
motion study of home-based HIV testing activities is a
direct and continuous observation of tasks conducted by
fieldworkers at home. This survey assesses the propor-
tion of the fieldworkers’ workday spent on different ac-
tivities (HIV testing but also research activities like DBS
collection, questionnaires administration and data col-
lection control) and to estimate salary costs dedicated
specifically to research activities. Time taken to accom-
plish a task is recorded using a timekeeping device and
reported using a standardized time sheet. The survey is
implemented on randomly selected calendar days and
conducted by the supervisors involved in the fieldwork
supervision.Health care professionals survey
A quantitative survey will be conducted in 2015 (during
phase 2) among health care providers in charge of
PLWHIV and working in the facilities included in the
TasP trial, both the TasP trial clinics and the DoH fixed
clinics. Data will be collected using a quantitative survey
instrument previously used in a research programme
with HIV care medical professionals in Cameroon [58].
Data collected will include information on socio-
demographic characteristics of the health care profes-
sionals, training and experience in HIV care, working
conditions, practices and knowledge about HIV and
ART management, opinions about the UTT strategy.
In addition, data relating to the characteristics of the
TasP trial clinics will be obtained through access to insti-
tutional reports, computer systems and interviews of
each health centre’s managers and staff: types of health
services, size of HIV clientele, number of ART-treated
patients, human resources in charge of HIV care, work-
ing time devoted to the care of PLWHIV and staff com-
pensation to estimate the cost of human resources
involved in patient care.Ethics approval
Prior to the study implementation, initial meetings were
organised with the Africa Centre Community Advisory
Board (CAB) which is comprised of representatives of
local traditional authorities, community members, local
government and non-governmental organisation stake-
holders. The CAB provided approval for the trial to take
place in the local communities and is also kept informed
of progress. Regularly scheduled community road shows
are conducted both in control and intervention clusters
to ensure continuous feedback between the investigators
and the communities.The social science programme of the ANRS 12249 TasP
trial was approved by the Biomedical Research Ethics
Committee (BREC) of the University of KwaZulu-Natal
on 26 September 2012. The trial is being conducted with
the permission of the KwaZulu-Natal DoH, South Africa
(granted on 19 July 2011) and the South African Medi-
cines Control Council (MCC) (granted on 28 June 2012).
Our consent procedures include: at home level, for
each survey round, (i) verbal consent of the homestead’s
owner to enter the homestead; (ii) verbal consent of the
head of household to register household members and
to contact them; (iii) written individual consent to
complete the individual questionnaire and/or to provide
a DBS; (iv) written individual consent for HIV rapid test;
at TasP trial clinics level (v) individual written consent
to receive HIV care and for collection of clinical and
behavioural data by trial nurses and counsellors; (vi) separ-
ate written consent for each independent interviewer-
administered questionnaire; and at community level (vii)
written consent of each participant involved in focus
groups or in-depth interviews.
All consent procedures and forms have been approved
by the BREC. For participants aged 16 or 17, we collect
both the consent of the participant and the consent of a
parent or a guardian. The BREC is aware that some of
the participants are minors and has approved the age
range of participation and the specific consent procedure
for minors.
Discussion
Substantial social consequences may be expected, as a
result to UTT implementation, such as changes in social
representations of HIV transmission and prevention, of
HIV testing, of ART use, and changes in individual per-
ceptions and behaviours in terms of uptake of testing,
frequency of testing, and ART initiation at high CD4
count, among others. The triangulation of several social
science studies within the ANRS 12249 TasP trial will
provide comprehensive insight, complementary to clin-
ical and epidemiological outcomes, on the acceptability
and effectiveness of a UTT intervention at individual
(both HIV negative and positive), community, popula-
tion and health system level.
The social science research programme we have de-
signed within the ANRS 12249 TasP trial has a number
of limitations. First, in spite of the robust community-
based randomised controlled trial design within which
the social research programme is structured, it may be
difficult to disentangle the drivers of the social changes
in the trial communities, from other research effects in
communities under prolonged scrutiny.
Non-resident household members are not eligible to
participate in the trial and only a limited number of their
characteristics will be documented. Additional data
Orne-Gliemann et al. BMC Public Health  (2015) 15:209 Page 12 of 14collection targeting non-residents would be required to
fully explore how in- and out-migration influences the
feasibility and efficacy of UTT.
The social science research programme of the ANRS
12249 TasP trial, like the social science components in
other ongoing UTT trials, will not be able to answer emer-
ging public health and operational questions relating to
operational scale-up of UTT interventions. In the next few
years, UTT strategy, in one guise or another, is likely to be
rolled-out in different low and middle-income country con-
texts. However bringing any UTT strategy to scale is going
to be a complex process that will require more than trial re-
sults to guide the policy and process decisions. Reflecting
back to Granich et al.’s original proposition [8] and the vast
literature and commentary that have followed, nowhere
have the mechanisms been defined for taking UTT beyond
scientific enquiry, to scale as public health policy [59].
Ensuring that policy-makers and implementers give due
consideration to the issues that surround such moves is es-
sential. Additional research beyond the trials and evaluation
studies will be required to provide evidence to guide policy
makers to ensure all the complex interactions of factors are
taken into consideration during implementation.
Finally, UTT relies on a programme of sustained inter-
vention elements enacted simultaneously, which will
likely need to be adapted and will likely evolve over time,
although as yet this is not well defined. Would continu-
ous provider-initiated regular and repeat HIV-testing re-
main acceptable? Or would alternative testing modalities
(such as self-testing or mobile-testing) be needed to keep
populations engaged and to identify new HIV infections
as early as possible? As levels of understanding of UTT
strategies in communities improve, will linking newly di-
agnosed patients – without any visible symptoms or per-
ceived HIV-risk – into treatment and care become
easier or more difficult? Will specific linkage to care in-
terventions be required to encourage and support people
to begin immediate ART treatment? Which models of
care would be the most appropriate to UTT scale-up?
Are there likely to be long-term social and behavioural
consequences of large numbers of people in a given
community knowing their HIV-status and starting treat-
ment early? The follow-up period planned within our
studies will not allow us to respond to all these ques-
tions, nor will our trial be able to address all the long
term impacts of a sustained UTT intervention.
In spite of these limitations, the social science research
programme of the ANRS 12249 TasP trial, designed as a
rigorous and comprehensive package of studies, and
employing different disciplinary approaches, will be in-
strumental in advancing understanding of barriers and
facilitators of the continuum of HIV testing and care
and the potential impact of UTT intervention strategies
as public health interventions.Additional file
Additional file 1: Composition of the TasP Study Group.
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